- Drug Pipelines
- September 2022
- 30 Pages
Global
From €2838EUR$3,250USD£2,466GBP
From €3057EUR$3,500USD£2,655GBP
- Report
- January 2025
- 85 Pages
Saudi Arabia
From €3057EUR$3,500USD£2,655GBP
- Report
- January 2025
- 85 Pages
Saudi Arabia
From €3057EUR$3,500USD£2,655GBP
- Report
- December 2024
- 85 Pages
Spain
From €3057EUR$3,500USD£2,655GBP
From €3057EUR$3,500USD£2,655GBP
- Report
- October 2024
- 82 Pages
Saudi Arabia
From €3057EUR$3,500USD£2,655GBP
- Report
- September 2024
- 82 Pages
Japan
From €3057EUR$3,500USD£2,655GBP
- Report
- September 2024
- 80 Pages
France
From €3057EUR$3,500USD£2,655GBP
- Report
- August 2024
- 80 Pages
United States
From €3057EUR$3,500USD£2,655GBP
- Report
- August 2024
- 128 Pages
Europe
From €3493EUR$4,000USD£3,035GBP
- Report
- August 2024
- 80 Pages
Japan
From €3057EUR$3,500USD£2,655GBP
- Report
- July 2024
- 182 Pages
Global
From €3930EUR$4,500USD£3,414GBP
- Report
- May 2024
- 182 Pages
Global
From €3930EUR$4,500USD£3,414GBP
- Report
- May 2024
- 187 Pages
Global
From €3930EUR$4,500USD£3,414GBP
- Report
- May 2024
- 182 Pages
Global
From €3930EUR$4,500USD£3,414GBP
- Report
- May 2024
- 185 Pages
Global
From €3930EUR$4,500USD£3,414GBP
- Report
- May 2024
- 185 Pages
Global
From €3930EUR$4,500USD£3,414GBP
- Report
- April 2024
- 88 Pages
France
From €3057EUR$3,500USD£2,655GBP
- Report
- April 2024
- 180 Pages
Global
From €3930EUR$4,500USD£3,414GBP

The Targeted Therapies market within the context of Genomics is focused on the development of treatments that target specific genetic mutations or pathways. These therapies are designed to be more effective and have fewer side effects than traditional treatments. Genomics has enabled the development of personalized treatments that are tailored to the individual patient's genetic makeup. This has allowed for the development of drugs that target specific mutations or pathways, leading to more effective treatments.
The Targeted Therapies market is a rapidly growing field, with many companies investing in research and development. Companies such as Gilead Sciences, Novartis, and AstraZeneca are leading the way in the development of targeted therapies. Other companies such as Merck, Pfizer, and Roche are also investing in the development of targeted therapies. Show Less Read more